Alpha
Emitter Market Size and Growth Rate:
According to the Research Report published by Research Cosmos ,the global
alpha emitter market was estimated at USD 506.50 million in 2018, and it is
expected to be valued USD 3302.9 million by 2024,registering a CAGR of 36.6%
over the forecast period of 2019-2025.
Browse details of 150 number of pages
research report developed on Alpha
Emitter Market @
Alpha
Emitter Market Growth Drivers and Restraints:
Main drivers contributing to the growth of the
market are rising incidences of cardiac & cancer ailments, raised awareness
about the potential advantages of targeted alpha therapy and the growing
availability of radiopharmaceuticals.
Shorter life of radiopharmaceuticals, need for
high capital investment, rigorous regulatory framework and restitution issues
are the main factors impacting market growth.
Main drivers contributing to the growth of the
alpha emittermarket are rising incidences of cardiac & cancer ailments,
raised awareness about the potential advantages of targeted alpha therapy and
the growing availability of radiopharmaceuticals.Alpha emitter offers many
improvements when compared to beta emitters and photon therapy, thus giving it
a frequently favored mode of treatment.North America accounted for the largest
share in 2017, followed by Europe and Asia-Pacific.
Alpha
Emitter Market Segmentation:
The global alpha emitters market is segmented
based on radionuclide type, medical utilization, end user and geography. Based
on radionuclide model, the market is divided into Actinium, Astatine (At-211),
Bismuth, Bismuth (Bi-212), Lead (Pb-212), Radium and Terbium (Tb-149). Alpha
emitter offers many improvements when compared to beta emitters and photon
therapy, thus giving it a frequently favored mode of treatment. As a result,
this has caught the notice of key companies interested in realizing the market
potential. The medical application section is categorized into bone metastasis,
endocrine tumors, lymphoma, melanoma, ovarian cancer, pancreatic cancer, and
thyroid. Alpha emitter medicine holds a great promise when related to
chemotherapy as targeted alpha therapy allows clear discrimination among the
healthy cells and cancer cells, and hence are effectively used for the
treatment of cancers including ovarian carcinoma, pancreatic cancer etc.
Alpha
Emitter Market Geographical Insights:
North America accounted for the largest share in
2017, followed by Europe and Asia-Pacific. Circumstances such as high-end
research course in the United States, coupled with high advances in healthcare
study and abundant knowledge in cancer research are feeding the growth in North
America. In addition to this, the search for alpha emitters is increasing in
developing markets such as China and India due to increasing disposable income,
raising healthcare standards and reforms in foreign policies. The Asia-Pacific
region is expected to grow at a lucrative rate over the forecast period.
Growing government initiatives and trends toward the adoption of
technologically-advanced outcomes for healthcare are some of the main factors
responsible for this growth.
Ask Free Sample of the report @ https://www.researchcosmos.com/request/alpha-emitter-market/22331350
KeyPlayers
of the Alpha Emitter Market:
- Actinium Pharmaceutical Inc.
- Alpha Tau Medical Ltd
- Bayer AG
- Fusion Pharmaceuticals
- IBA Radiopharma Solutions
- RadioMedix Inc.
- Telix Pharmaceuticals Ltd
For
any queries, inquire more @ https://www.researchcosmos.com/inquire/alpha-emitter-market/22331350
About Us:
Research Cosmos is a provider of
standard and customized market research, business intelligence and consulting
services across more than 100 domains in different industries of the world. We
host the trending market reports of the world’s top-notch publishing companies,
offering services to a wide range of customers from students to fortune 500
companies and discloses the hidden opportunities in every leading industry of
the world.
Contact:
Kevin Stewart
Global Sales
Manager
Research Cosmos
No comments:
Post a Comment